Literature DB >> 19190807

Shiga toxins, glycosphingolipid diversity, and endothelial cell injury.

Johannes Müthing1, Christian H Schweppe, Helge Karch, Alexander W Friedrich.   

Abstract

Shiga toxin (Stx)-producing Escherichia coli (STEC) cause an enteric illness that results in a spectrum of outcomes ranging from asymptomatic carriage to uncomplicated diarrhea, bloody diarrhea, and the postdiarrheal haemolytic uremic syndrome (HUS), which leads to renal and other organ microvascular thrombosis. Binding of Stx to the glycosphingolipid (GSL) globotriaosylceramide (Gb3Cer/CD77) on endothelial cells followed by receptor-mediated endocytosis is the linchpin in STEC-mediated disease. Only GSLs that associate strongly with lipid rafts appear to carry Stxs retrogradely from the plasma membrane through the Golgi apparatus to the endoplasmic reticulum where they are translocated to the cytosol and exert their toxic function. Thus, the biophysical features of the lipid moiety of GSL receptors may influence its incorporation into certain membrane domains and thereby affect toxin destination. Consequently, a detailed structural analysis of Stx-binding GSLs is required to illuminate the molecular causes that may underlie the different Stx susceptibilities of endothelial cells derived from various vascular beds. Solid phase overlay binding assays of thin-layer chromatography (TLC)-separated GSL preparations employing specific antibodies and/or Stxs in conjunction with anti-Stx-antibodies are commonly used for the identification of Stx-binding GSLs. Such GSL-profiling combined with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) represents a convenient strategy to structurally characterize Stx-receptors from any biological sources such as primary cells, cell lines, or organs. This approach may be helpful to gain insights into Stx-induced impairment of target cells that is suggested to originate at least partly from the structural heterogeneity of the cellular ligands of Stxs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190807

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  47 in total

1.  Neutral glycosphingolipids in human blood: a precise mass spectrometry analysis with special reference to lipoprotein-associated Shiga toxin receptors.

Authors:  Christian H Schweppe; Petra Hoffmann; Jerzy-Roch Nofer; Gottfried Pohlentz; Michael Mormann; Helge Karch; Alexander W Friedrich; Johannes Müthing
Journal:  J Lipid Res       Date:  2010-05-05       Impact factor: 5.922

Review 2.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  Sensitive detection of Shiga Toxin 2 and some of its variants in environmental samples by a novel immuno-PCR assay.

Authors:  Xiaohua He; Wenyuan Qi; Beatriz Quiñones; Stephanie McMahon; Michael Cooley; Robert E Mandrell
Journal:  Appl Environ Microbiol       Date:  2011-03-25       Impact factor: 4.792

Review 4.  Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure.

Authors:  Bradley S Podd; Dennis W Simon; Santiago Lopez; Andrew Nowalk; Rajesh Aneja; Joseph A Carcillo
Journal:  Pediatr Clin North Am       Date:  2017-08-18       Impact factor: 3.278

Review 5.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2014-05-26       Impact factor: 10.946

Review 6.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

7.  Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.

Authors:  Jun Fujii; Mariko Naito; Takashi Yutsudo; Sohkichi Matsumoto; Daniel P Heatherly; Takeshi Yamada; Hideyuki Kobayashi; Shin-Ichi Yoshida; Tom Obrig
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

8.  Top-down proteomic identification of Shiga toxin 2 subtypes from Shiga toxin-producing Escherichia coli by matrix-assisted laser desorption ionization-tandem time of flight mass spectrometry.

Authors:  Clifton K Fagerquist; William J Zaragoza; Omar Sultan; Nathan Woo; Beatriz Quiñones; Michael B Cooley; Robert E Mandrell
Journal:  Appl Environ Microbiol       Date:  2014-02-28       Impact factor: 4.792

9.  Association of Shiga toxin glycosphingolipid receptors with membrane microdomains of toxin-sensitive lymphoid and myeloid cells.

Authors:  Ivan U Kouzel; Gottfried Pohlentz; Wiebke Storck; Lena Radamm; Petra Hoffmann; Martina Bielaszewska; Andreas Bauwens; Christoph Cichon; M Alexander Schmidt; Michael Mormann; Helge Karch; Johannes Müthing
Journal:  J Lipid Res       Date:  2012-12-17       Impact factor: 5.922

Review 10.  Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Ramon Alfonso Exeni; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Gabriela Alejandra Fiorentino; Andrea Mariana Exeni; Maria Victoria Ramos; Marina Sandra Palermo
Journal:  Pediatr Nephrol       Date:  2018-01-25       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.